StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of NASDAQ EVOK opened at $3.78 on Wednesday. Evoke Pharma has a 52-week low of $3.44 and a 52-week high of $12.32. The firm has a 50 day moving average price of $4.58 and a 200 day moving average price of $4.73. The stock has a market cap of $5.62 million, a P/E ratio of -0.34 and a beta of 0.12.

Institutional Trading of Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC lifted its holdings in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned 9.95% of Evoke Pharma worth $655,000 as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.